TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16683469

Group type: EXPERIMENTAL
Intervention: Listening efforts with varied levels and frequencies of target sound and ambient noise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Listening efforts with varied levels and frequencies of target sound
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra-individual variation in earprints
Number of subjects: 40
Study: 15286069

Group type: EXPERIMENTAL
Intervention: Feedback from a standardised assessment of need
Number of subjects: 304

Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 304
Study: 11029005

Group type: EXPERIMENTAL
Intervention: Supervised treatment interruptions (one or two)
Number of subjects: 8
Study: 9342132

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8237807

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3551674

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 101
Study: 29801739

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (routine early coronary angiography and PCI)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 881
Study: 28735031

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Subcutaneous fentanyl
Number of subjects: 116

Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 116
Study: 24665871

Group type: EXPERIMENTAL
Intervention: Irrigation with ozonated water after subgingival scaling and root planing (SRP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Subgingival scaling and root planing (SRP) followed by irrigation with distilled water
Number of subjects: 41
Study: 23505301

Group type: EXPERIMENTAL
Intervention: Galectin-3 levels measured at baseline and 24 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Galectin-3 in patients with supramedian baseline LV ejection fraction (>49.2%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of galectin-3 with matrix metalloproteinase-3 and monocyte chemoattractant protein-1
Number of subjects: 100
Study: 21962393

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT after autologous HSCT (auto-allo group)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Tandem autologous HSCT (auto-auto group)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Maintenance therapy (thalidomide plus dexamethasone)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 710
Study: 19142466

Group type: EXPERIMENTAL
Intervention: Audio-visual computerized remediation program (Play on) in students with developmental dyslexia (GIe)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Audio-visual computerized remediation program (Play on) in good readers (GIIe)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention in students with developmental dyslexia (GIc)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention in good readers (GIIc)
Number of subjects: 20
Study: 16382442

Group type: EXPERIMENTAL
Intervention: Ouabain infusion (0.4 mug.min(‐1).dl(‐1))
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (no ouabain infusion)
Number of subjects: 3
Study: 12805250

Group type: EXPERIMENTAL
Intervention: Enriched drink with essential vitamins and minerals (30% to 150% of RDA and higher levels of antioxidants), taken twice a day for six months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo drink, taken twice a day for six months
Number of subjects: 55
Study: 12768686

Group type: EXPERIMENTAL
Intervention: Partial laryngectomy with preoperative radiotherapy (dose 40-50Gy)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Partial laryngectomy with postoperative radiotherapy (dose 51-70 Gy)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Partial laryngectomy alone
Number of subjects: 171
Study: 8816197

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2065035

Group type: EXPERIMENTAL
Intervention: 2.5 mg simvastatin q.a.m.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 2.5 mg simvastatin q.p.m.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 5 mg simvastatin q.a.m.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 5 mg simvastatin q.p.m.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Evening regimen (both dosages)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 6127790

Group type: EXPERIMENTAL
Intervention: Treatment with propantheline and antacids
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Treatment with cimetidine and antacids
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Medical treatment (unspecified)
Number of subjects: 67
Study: 31780277

Group type: COMPARATOR
Intervention: Standard-dose indometacin (two 50 mg suppositories + placebo)
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: High-dose indometacin (three 50 mg suppositories + additional 50 mg after 4 hours)
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Standard-dose indometacin
Number of subjects: 1037

Group type: EXPERIMENTAL
Intervention: High-dose indometacin
Number of subjects: 1037
Study: 30763131

Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 28093625

Group type: EXPERIMENTAL
Intervention: Ultralow dose CT (0.13 ± 0.01 mSv)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard dose CT (1.8 ± 0.7 mSv)
Number of subjects: 202
Study: 26082615

Group type: EXPERIMENTAL
Intervention: Fimasartan/HCTZ 12.5 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Fimasartan 60 mg
Number of subjects: 256
Study: 24079295

Group type: EXPERIMENTAL
Intervention: Complex intervention including training in health centre management, fever case management with rapid diagnostic tests (RDTs) for malaria, patient-centered services, and provision of artemether-lumefantrine (AL) and RDTs.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Current standard of care (control group).
Number of subjects: 20
Study: 22168805

Group type: EXPERIMENTAL
Intervention: 2.84 mL of lidocaine with epinephrine plus 0.5 M mannitol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 mL of lidocaine with epinephrine plus 0.5 M mannitol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.8 mL of lidocaine with epinephrine (control solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine formulations without mannitol
Number of subjects: 40
Study: 19630582

Group type: EXPERIMENTAL
Intervention: scent cues
Number of subjects: 20

Group type: COMPARATOR
Intervention: no scent cues
Number of subjects: 20
Study: 16495694

Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrocolic duodenojejunostomy
Number of subjects: 40
Study: 14722590

Group type: EXPERIMENTAL
Intervention: Educational intervention (8-hour program)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (11 nurses from the same unit)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (19 nurses from a different unit)
Number of subjects: 44
Study: 10874660

Group type: EXPERIMENTAL
Intervention: Surface electromyography assessment in CLBP patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-pain control subjects
Number of subjects: 30
Study: 8443900

Group type: EXPERIMENTAL
Intervention: Balloon coarctation angioplasty
Number of subjects: 36

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 3533084

Group type: EXPERIMENTAL
Intervention: suprofen 200 mg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: lysine acetylsalicylate 0.9 g/2.5 ml
Number of subjects: 60
Study: 30337745

Group type: EXPERIMENTAL
Intervention: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol for 3 days before operation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group without preoperative aerosol inhalation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxygen drive aerosol inhalation with 2 mg budesonide and 60 mg ambroxol
Number of subjects: 80
Study: 27048692

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy in patients without intravenous alteplase treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intra-arterial therapy in patients with intravenous alteplase treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Safety parameters and serious adverse events
Number of subjects: 55
Study: 24329132

Group type: EXPERIMENTAL
Intervention: Medium-dose ultrasound (1.5 Watt/cm(2))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-power pain threshold ultrasound (HPPT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low-dose ultrasound (0.5 W/cm(2))
Number of subjects: 61
Study: 22522994

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 21269038

Group type: EXPERIMENTAL
Intervention: Colgate Total (0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Crest Pro-Health (0.454% stannous fluoride, sodium hexametaphosphate, zinc lactate)
Number of subjects: 75
Study: 18449450

Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD) 0.6-0.8 g/kg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal protein diet (NPD) 1.0-1.2 g/kg per day
Number of subjects: 60
Study: 15616227

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 19
Study: 12721262

Group type: EXPERIMENTAL
Intervention: 20% BCNU polymer
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 28% BCNU polymer
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 6.5%, 10%, 14.5% BCNU polymers
Number of subjects: 44
Study: 10486676

Group type: EXPERIMENTAL
Intervention: Dippers
Number of subjects: 245

Group type: COMPARATOR
Intervention: Non dippers
Number of subjects: 245
Study: 8618369

Group type: EXPERIMENTAL
Intervention: Calcium carbonate antacid tablets (Tums, 1000 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Famotidine (Pepcid AC, 10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1565534

Group type: EXPERIMENTAL
Intervention: Once daily oral cefixime (8 mg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Twice daily oral trimethoprim/sulfamethoxazole (TMP/SMX) (8/40 mg/kg/day)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 4084979

Group type: EXPERIMENTAL
Intervention: Low-level tension at 5% of individual maximum (Group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-level tension at 30% of individual maximum (Group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 48
Study: 31564601

Group type: EXPERIMENTAL
Intervention: Tu Salud ¡Si Cuenta! (Your Health Matters!) at Home Intervention, 6 monthly CHW visits
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care (community‐wide health promotion campaign)
Number of subjects: 500
Study: 29771700

Group type: EXPERIMENTAL
Intervention: IV amino acid supplementation (up to 100g daily to achieve 2.0g/kg/d)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: IV amino acid supplementation
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 474
Study: 27278405

Group type: EXPERIMENTAL
Intervention: Polyphenol- and fibre-rich foods (PFRF) - lower dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Polyphenol- and fibre-rich foods (PFRF) - higher dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Polyphenol- and fibre-rich foods (PFRF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (bread, water, balancing sugars)
Number of subjects: 16
Study: 24885551

Group type: EXPERIMENTAL
Intervention: Intensified inpatient DBT for 12 weeks plus six months of standard DBT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard outpatient DBT
Number of subjects: 70
Study: 22298313

Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract surgery
Number of subjects: 30
Study: 19887440

Group type: COMPARATOR
Intervention: Home exercise programme
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 70
Study: 18519460

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer and quaternary ammonium wipes for surface disinfection for 8 weeks
Number of subjects: 285

Group type: COMPARATOR
Intervention: Usual hand-washing and cleaning practices
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer and quaternary ammonium wipes for surface disinfection
Number of subjects: 285
Study: 16084125

Group type: COMPARATOR
Intervention: 50 mg melatonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mg melatonin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11976989

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and didanosine (PANDAs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PANDAs
Number of subjects: 16

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 16
Study: 10713863

Group type: EXPERIMENTAL
Intervention: Rhinogen (hyaluronic acid containing cream)
Number of subjects: 56

Group type: COMPARATOR
Intervention: H.E.C. (ointment)
Number of subjects: 56
Study: 7586621

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (5 micrograms/kg/min i.v. for a median of 109 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine infusion (continued)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine withdrawal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine infusion (continued and interrupted)
Number of subjects: 20
Study: 1735342

Group type: EXPERIMENTAL
Intervention: Percutaneous drainage using ultrasound guidance followed by intralesional nitroimidazole administration
Number of subjects: 51

Group type: COMPARATOR
Intervention: Medical therapy with nitroimidazoles
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open surgical drainage
Number of subjects: 51
Study: 6437487

Group type: EXPERIMENTAL
Intervention: Day hospital rehabilitation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (managed as before day hospital care)
Number of subjects: 120
Study: 31618060

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29923977

Group type: EXPERIMENTAL
Intervention: Leukosan SkinLink (LS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Surgical suture (SS)
Number of subjects: 49
Study: 27879183

Group type: EXPERIMENTAL
Intervention: Personalised self-management support using the SeMaS questionnaire
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 644
Study: 24269833

Group type: EXPERIMENTAL
Intervention: 0.014in. NiTi wire
Number of subjects: 71

Group type: COMPARATOR
Intervention: Rectangular NiTi wires
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bracket type
Number of subjects: 71
Study: 22691136

Group type: EXPERIMENTAL
Intervention: Cognitive defusion (CD)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 110
Study: 20581302

Group type: EXPERIMENTAL
Intervention: Surgical management, radiation therapy, and systemic therapy for pelvic bone sarcomas
Number of subjects: 0
Study: 17593235

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0.2 U/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insulin lispro (0.2 U/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (0.4 U/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insulin lispro (0.4 U/kg)
Number of subjects: 80
Study: 16279152

Group type: EXPERIMENTAL
Intervention: Supported arm exercise (SAE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Unsupported arm exercise (UAE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leg exercise (LE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume to total lung capacity ratio during SAE
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: End-expiratory lung volume to total lung capacity ratio during LE
Number of subjects: 8
Study: 12466870

Group type: COMPARATOR
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Gamma Nail
Number of subjects: 250
Study: 9988396

Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT)
Number of subjects: 70
Study: 7771479

Group type: EXPERIMENTAL
Intervention: Microalbuminuria and macroalbuminuria
Number of subjects: 933
Study: 2178521

Group type: EXPERIMENTAL
Intervention: Azelastine 6 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Azelastine (all doses)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 6945911

Group type: EXPERIMENTAL
Intervention: Vindesine (VND)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Vincristine (VCR)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: First relapsers (both VND and VCR)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Subsequent relapsers (both VND and VCR)
Number of subjects: 179
Study: 30880443

Group type: EXPERIMENTAL
Intervention: fasiglifam (25 mg, 50 mg)
Number of subjects: 7595

Group type: EXPERIMENTAL
Intervention: fasiglifam
Number of subjects: 7595

Group type: COMPARATOR
Intervention: placebo or active control
Number of subjects: 7595
Study: 28658202

Group type: EXPERIMENTAL
Intervention: TacHexal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prograf
Number of subjects: 0
Study: 26496519

Group type: EXPERIMENTAL
Intervention: FOCUS Program
Number of subjects: 34
Study: 24617776

Group type: EXPERIMENTAL
Intervention: Social comparison intervention (20 min computer-tailored interview in audio format)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention (control condition)
Number of subjects: 150
Study: 22281416

Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Flexible(APC) regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Conventional 24/4 regimen (ethinylestradiol 20 mcg/drospirenone 3 mg)
Number of subjects: 1864
Study: 20658805

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Cognitive Therapy only
Number of subjects: 308

Group type: COMPARATOR
Intervention: Written Accounts
Number of subjects: 308
Study: 17967671

Group type: EXPERIMENTAL
Intervention: High-frequency/low-volume ventilation with 100% oxygen (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-frequency/low-volume ventilation with 21% oxygen (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cm H(2)O with 100% oxygen (group 3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure of 5 cm H(2)O with 21% oxygen (group 4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Passive deflation (group 5)
Number of subjects: 50
Study: 15310939

Group type: EXPERIMENTAL
Intervention: NNRTI-based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/tenofovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Didanosine/lamivudine/tenofovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emtricitabine-containing treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily abacavir regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily lopinavir/ritonavir regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Didanosine 400 mg/tenofovir regimens
Number of subjects: 0
Study: 12437764

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 3577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study: 9604358

Group type: EXPERIMENTAL
Intervention: Noise bursts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency-modulated tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trains of short noise bursts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for azimuth response components
Number of subjects: 0
Study: 8553146

Group type: EXPERIMENTAL
Intervention: 1.8 mg buserelin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3.6 mg buserelin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 7.2 mg buserelin
Number of subjects: 32
Study: 2700103

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg in a single morning dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ranitidine 300 mg in a single nocte dose
Number of subjects: 55
Study: 797044

Group type: EXPERIMENTAL
Intervention: delta1-tetrahydrocannabinol (THC) 200 mug in ethanol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: salbutamol 100 mug (Ventolin inhaler)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo-ethanol only
Number of subjects: 10